These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11429125)

  • 21. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.
    Patterson LJ; Malkevitch N; Zhao J; Peng B; Robert-Guroff M
    DNA Cell Biol; 2002 Sep; 21(9):627-35. PubMed ID: 12396605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.
    Demberg T; Boyer JD; Malkevich N; Patterson LJ; Venzon D; Summers EL; Kalisz I; Kalyanaraman VS; Lee EM; Weiner DB; Robert-Guroff M
    J Virol; 2008 Nov; 82(21):10911-21. PubMed ID: 18753198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge.
    Tuero I; Mohanram V; Musich T; Miller L; Vargas-Inchaustegui DA; Demberg T; Venzon D; Kalisz I; Kalyanaraman VS; Pal R; Ferrari MG; LaBranche C; Montefiori DC; Rao M; Vaccari M; Franchini G; Barnett SW; Robert-Guroff M
    PLoS Pathog; 2015 Aug; 11(8):e1005101. PubMed ID: 26267144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection from pathogenic SIV challenge using multigenic DNA vaccines.
    Haigwood NL; Pierce CC; Robertson MN; Watson AJ; Montefiori DC; Rabin M; Lynch JB; Kuller L; Thompson J; Morton WR; Benveniste RE; Hu SL; Greenberg P; Mossman SP
    Immunol Lett; 1999 Mar; 66(1-3):183-8. PubMed ID: 10203053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants.
    Zhao J; Lou Y; Pinczewski J; Malkevitch N; Aldrich K; Kalyanaraman VS; Venzon D; Peng B; Patterson LJ; Edghill-Smith Y; Woodward R; Pavlakis GN; Robert-Guroff M
    Vaccine; 2003 Sep; 21(25-26):4022-35. PubMed ID: 12922139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.
    Patterson LJ; Malkevitch N; Pinczewski J; Venzon D; Lou Y; Peng B; Munch C; Leonard M; Richardson E; Aldrich K; Kalyanaraman VS; Pavlakis GN; Robert-Guroff M
    J Virol; 2003 Aug; 77(16):8607-20. PubMed ID: 12885879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
    Patterson LJ; Beal J; Demberg T; Florese RH; Malkevich N; Venzon D; Aldrich K; Richardson E; Kalyanaraman VS; Kalisz I; Lee EM; Montefiori DC; Robey FA; Robert-Guroff M
    Virology; 2008 May; 374(2):322-37. PubMed ID: 18252262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge.
    Yasutomi Y; Koenig S; Woods RM; Madsen J; Wassef NM; Alving CR; Klein HJ; Nolan TE; Boots LJ; Kessler JA
    J Virol; 1995 Apr; 69(4):2279-84. PubMed ID: 7884874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
    Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Replicating Adenovirus-SIV Immunization of Rhesus Macaques Induces Mucosal Dendritic Cell Activation and Function Leading to Rectal Immune Responses.
    Ko EJ; Helmold Hait S; Enyindah-Asonye G; Rahman MA; Hoang T; Robert-Guroff M
    Front Immunol; 2019; 10():779. PubMed ID: 31031768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.
    Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ
    J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors.
    Virnik K; Nesti E; Dail C; Hockenbury M; Ni Y; Felber BK; Schief WR; Berkower I
    Vaccine; 2017 May; 35(24):3272-3278. PubMed ID: 28483193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant Herpesvirus Vectors: Durable Immune Responses and Durable Protection against Simian Immunodeficiency Virus SIVmac239 Acquisition.
    Castro IM; Ricciardi MJ; Gonzalez-Nieto L; Rakasz EG; Lifson JD; Desrosiers RC; Watkins DI; Martins MA
    J Virol; 2021 Jun; 95(14):e0033021. PubMed ID: 33910957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML
    J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge.
    Alpert MD; Rahmberg AR; Neidermyer W; Ng SK; Carville A; Camp JV; Wilson RL; Piatak M; Mansfield KG; Li W; Miller CJ; Lifson JD; Kozlowski PA; Evans DT
    J Virol; 2010 Oct; 84(20):10748-64. PubMed ID: 20702641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences between T cell epitopes recognized after immunization and after infection.
    Vogel TU; Horton H; Fuller DH; Carter DK; Vielhuber K; O'Connor DH; Shipley T; Fuller J; Sutter G; Erfle V; Wilson N; Picker LJ; Watkins DI
    J Immunol; 2002 Oct; 169(8):4511-21. PubMed ID: 12370388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.